Literature summary for 3.1.1.4 extracted from

Tai, N.; Kuwabara, K.; Kobayashi, M.; Yamada, K.; Ono, T.; Seno, K.; Gahara, Y.; Ishizaki, J.; Hori, Y.
Cytosolic phospholipase A2 alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model (2010), Inflamm. Res., 59, 53-62.

Search for more literature for 3.1.1.4

Application

Application	Comment	Organism
drug development	potential therapeutic role for cPLA2 alpha inhibitors in the treatment of human rheumatoid arthritis. Oral administration of pyrroxyphene achieves anti-arthritic activity through inhibition of cPLA2 alpha activity, which leads to a reduction in eicosanoid levels and suppression of matrix metalloproteinases and cyclooxygenase-2 mRNA expression	Mus musculus

Inhibitors

Inhibitors	Comment	Organism	Structure
pyrroxyphene	significantly inhibits both the increase in levels of cPLA2 alpha and eicosanoids as well as the mRNA expression of matrix metalloproteinase-3, -8, -9, -13, and cyclooxygenase-2. Strongly inhibits the incidence of arthritis and bone destruction	Mus musculus

Localization

Localization	Comment	Organism	GeneOntology No.	Textmining

Metals/Ions

Metals/Ions	Comment	Organism	Structure
Ca2+	required for catalysis	Mus musculus

Organism

Organism	UniProt	Comment	Textmining
Mus musculus	-	male DBA/1J mice	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
1-palmitoyl-2-arachidonoylphosphatidylcholine + H2O	-	Mus musculus	1-palmitoyl-glycerophosphorylcholine + arachidonic acid	-	?

Synonyms

Synonyms	Comment	Organism
cPLA2 alpha	-	Mus musculus
cytosolic phospholipase A2 alpha	-	Mus musculus

General Information

General Information	Comment	Organism
physiological function	cPLA2 alpha plays an important role in the pathogenesis of collagen-induced arthritis. cPLA2 alpha activity increases in hind paws of collagen-induced arthritic mice	Mus musculus

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)